Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 132Ovarian Neoplasms 109Endometrial Neoplasms 80Uterine Cervical Dysplasia 19Papillomavirus Infections 17Breast Neoplasms 16Fallopian Tube Neoplasms 15Carcinoma, Ovarian Epithelial 15Colorectal Neoplasms 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Vulvar Neoplasms 10Neoplasm Metastasis 10Recurrence 9Prostatic Neoplasms 9Endometrial Hyperplasia 9Cervical Cancer Screening 9Acquired Immunodeficiency Syndrome 8Uterine Neoplasms 7Stomach Neoplasms 7Squamous Intraepithelial Lesions 6Locally Advanced Cervical Cancer 6Anus Neoplasms 6Vaginal Neoplasms 5Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pelvic Neoplasms 5Pancreatic Neoplasms 5Melanoma 5

Interventions

fluzoparib 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Platinum-sensitive Relapsed Ovarian Cancer × Gynecologic × Clear all
NCT06446206 2024-06-06

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

The First Hospital of Jilin University

Phase 2 Not yet recruiting
22 enrolled
Gynecologic

Platinum-sensitive Relapsed Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡